Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.44
+4.17 (2.03%)
AAPL  272.03
+5.85 (2.20%)
AMD  215.50
+18.90 (9.61%)
BAC  50.41
-0.66 (-1.30%)
GOOG  311.51
-0.18 (-0.06%)
META  640.21
+2.96 (0.46%)
MSFT  386.17
+1.70 (0.44%)
NVDA  193.18
+1.63 (0.85%)
ORCL  144.66
+3.34 (2.37%)
TSLA  404.01
+4.19 (1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.